Breast Cancer Clinical Research

The site focuses on neoplasms. It emphasizes various subtypes of breast cancer and aims to evaluate new therapies and improve patient outcomes.

  • Triple‑negative breast cancer
  • HER2‑negative disease
  • ER‑positive/HER2‑negative early breast cancer
  • High‑risk lobular carcinoma
  • Adjuvant treatment optimization

Researchers at Kreiskrankenhaus Torgau Johann Kentmann gGmbH are dedicated to advancing care for women across the disease spectrum.

Immunotherapy Advances

Studies investigate the use of immune checkpoint inhibitors combined with chemotherapy. The goal is to boost event‑free survival in patients with triple‑negative breast cancer.

  • Atezolizumab with neoadjuvant chemotherapy
  • Adjuvant continuation of immunotherapy
  • Impact on event‑free survival
  • Integration of immunotherapy into standard regimens

The hospital’s program seeks to bring cutting‑edge immune‑based treatments to the local community.

Targeted Endocrine and CDK Inhibition

Trials evaluate long‑term endocrine therapy together with CDK4/6 inhibitors. One focus is palbociclib. Another involves ribociclib. The aim is to replace chemotherapy in older patients with high‑risk ER‑positive/HER2‑negative disease.

  • Palbociclib as postoperative adjuvant option
  • Ribociclib combined with novel oral agents
  • Extended endocrine therapy duration
  • Reducing chemotherapy exposure

This approach aims to maintain efficacy while minimizing treatment‑related toxicity for senior patients.

Antibody‑Drug Conjugate Research

The investigation of sacituzumab govitecan focuses on improving invasive disease‑free survival. It targets patients with HER2‑negative breast cancer compared with standard physician‑chosen therapies.

  • Sacituzumab govitecan efficacy assessment
  • Comparison with standard treatment options
  • Invasive disease‑free survival outcomes
  • Targeted delivery of cytotoxic payload

Results could expand therapeutic choices for individuals with limited options.

Lobular Breast Cancer Innovation

A neoadjuvant study examines the combination of capivasertib. It is paired with fulvestrant for patients having primary high‑risk lobular breast cancer. The aim is to enhance pathological response rates.

  • Capivasertib plus fulvestrant regimen
  • High‑risk lobular carcinoma focus
  • Neoadjuvant treatment evaluation
  • Molecular targeting strategies

The trial reflects the site’s commitment to personalized therapy for distinct breast cancer subtypes.